Immunotherapy and Immune-related Toxicity in Lung Cancer
Part of the Oncology and TR Grand Rounds Series - Jarushka Naidoo, MB, BCH identifies single agent immunotherapy and chemo- immunotherapy in first-line NSCLC. Dr. Jarushka also reviews combination immune checkpoint blockades in first-line and other immune-related toxicities.
Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bloomberg-Kimmel Institute for Cancer Immunotherapy